Astrazeneca (NYSE:AZN – Get Free Report)‘s stock had its “sell” rating reaffirmed by Deutsche Bank Aktiengesellschaft in a research report issued to clients and investors on Tuesday,MarketScreener reports.
Other equities research analysts also recently issued reports about the company. Barclays reaffirmed a “buy” rating on shares of Astrazeneca in a research report on Monday, June 1st. Sanford C. Bernstein restated a “buy” rating on shares of Astrazeneca in a research note on Monday, May 4th. Weiss Ratings started coverage on Astrazeneca in a report on Wednesday, March 11th. They issued a “buy (b)” rating on the stock. Jefferies Financial Group reiterated a “buy” rating on shares of Astrazeneca in a report on Wednesday, May 13th. Finally, Morgan Stanley restated an “overweight” rating on shares of Astrazeneca in a research note on Wednesday, April 8th. Twelve analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Astrazeneca presently has a consensus rating of “Moderate Buy” and a consensus price target of $205.33.
Read Our Latest Stock Analysis on AZN
Astrazeneca Stock Performance
Astrazeneca (NYSE:AZN – Get Free Report) last posted its quarterly earnings data on Wednesday, April 29th. The company reported $2.58 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.52 by $0.06. The business had revenue of $15.29 billion during the quarter, compared to the consensus estimate of $14.93 billion. Astrazeneca had a net margin of 17.19% and a return on equity of 30.86%. As a group, analysts anticipate that Astrazeneca will post 9.52 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
Large investors have recently modified their holdings of the company. Pine Valley Investments Ltd Liability Co acquired a new position in shares of Astrazeneca in the 1st quarter valued at $478,000. Parallel Advisors LLC acquired a new stake in shares of Astrazeneca during the 1st quarter valued at about $1,719,000. Cozad Asset Management Inc. bought a new stake in Astrazeneca in the first quarter valued at about $1,271,000. Axiom Investment Management LLC bought a new stake in Astrazeneca in the first quarter valued at about $98,000. Finally, Summitry LLC acquired a new position in Astrazeneca in the first quarter worth about $297,000. 20.35% of the stock is currently owned by institutional investors and hedge funds.
Astrazeneca Company Profile
AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.
The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.
Featured Stories
- Five stocks we like better than Astrazeneca
- Apple’s Siri AI Was Finally Announced, So Why Is the Stock Tanking?
- Has Temu-Owner PDD’s Story Changed After Double Miss?
- Tanker Dividends Are Surging, But Income Investors Need to Watch the Cycle
- These 3 Stocks Lowered Their Share Counts Drastically in Q1
Receive News & Ratings for Astrazeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Astrazeneca and related companies with MarketBeat.com's FREE daily email newsletter.
